Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/μL

Journal of the Medical Association of Thailand

Volumn 91, Issue 2, 2008, Pages 159-165

  Manosuthi, Weerawat ^a,c   Sungkanuparph, Somnuek ^b   Tansuphaswadikul, Somsit ^a   Chottanapund, Suthat ^a   Mankatitham, Wiroj ^a   Chimsuntorn, Sukanya ^a   Sittibusaya, Chayanan ^a   Moolasart, Visal ^a   Chaovavanich, Achara ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Bamrasnaradura Infectious Diseases Institute   (Thailand)

Author keywords

GPOvir; Hepatitis; HIV; Incidence; Nevirapine; Risk factor

Indexed keywords

NEVIRAPINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; RISK FACTORS; SICKNESS IMPACT PROFILE;

EID: 40949110526     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. U.S. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 29, 2004 [cited 2004 Dec 7]. Available at: http://AIDSinfo.nih.gov.
2. Sabin CA, Fisher M, Churchill D, Pozniak A, Hay P, Easterbrook P, et al. Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. J Acquir Immune Defic Syndr 2001; 26: 462-5.
3. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65.
4. Ferrer E, Santamarina E, Domingo P, Fumero E, Ribera E, Knobel H, et al. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less. AIDS 2004; 18: 1727-9.
5. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179: 1116-23.
6. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
7. de Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003; 17: 2209-14.
8. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538-9.
9. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-9.
10. Reisler K. High hepatotoxicity rate seen among HAART patients. AIDS Alert 2001; 16: 118-9.
11. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl 1): S21-33.
12. Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000 MMWR Morb Mortal Wkly Rep 2001; 49: 1153-6.
13. Benn PD, Mercey DE, Brink N, Scott G, Williams IG. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357: 687-8.
14. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med 2002; 137: 146-7.
15. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV post-exposure prophylaxis for 2 health care workers. JAMA 2000; 284: 2723.
16. Gonzalez dR, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16: 290-1.
17. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-92.
18. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45.
19. Carr A, Vella S, de Jong MD, Sorice F, Imrie A, Boucher CA, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 1996; 10: 635-41.
20. Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29: 455-6.
21. Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000; 11: 336-7.
22. Maggiolo F, Arici C, Airoldi M, Ripamonti D, Quinzan G, Gregis G, et al. Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother 2007; 59: 569-72.
23. Geel J, Pitt J, Orrell C, Van Dyk M, Wood R. The effect of fluconazole on nevirapine pharmacokinetics Program and abstracts of the XV International AIDS Conference, 11-16 July 2004; Bangkok, Thailand; 2004: 369. [abstract WeOr1239]
24. Manosuthi W, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007; 7: 14.
25. Bleeker-Rovers CP, Kadir SW, van Leusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 2000; 57: 190-3.
26. Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai 2004; 87: 1349-54.
27. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20: 1621-6.
28. Walubo A, Barr S, Abraham AM. RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol 2006; 28: 423-31.